TCRX
TScan Therapeutics·NASDAQ
--
--(--)
--
--(--)
4.42 / 10
Netural
Analyst sentiment is neutral with a 4.42/10 score; 66.7% of ratings are strong buy but historical win rates are low (0-33.3%). Fund-flow metrics are more encouraging at 7.68/10, indicating robust capital inflows despite recent price declines. The contrast between positive fund flows and lukewarm analyst confidence adds nuance to the overall assessment.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
67%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-11-13
InstitutionHC Wainwright & Co.
Times predicted1
Historical Win Rate0.0%
What is the analyst consensus for TCRX?
- TCRX holds a Bearish analyst rating, with 67% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 4.42/10 (Netural).
